Evidence map›Paper›PMID 33657133›Full record

ArticlePLoS neglected tropical diseases2021

Schistosoma mansoni alter transcription of immunomodulatory gene products following in vivo praziquantel exposure.

Paul McCusker, Claudia M Rohr, John D Chan

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Mechanistic insights intoJournal of advanced veterinary and animal research · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Development of non-sedating benzodiazepines withAntimicrobial agents and chemotherapy · 2024
    Article
  8. Article
  9. Translating From Egg- to Antigen-Based Indicators forFrontiers in tropical diseases · 2022
    Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Paul McCuskerDepartment of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, United States of America.ORCID 0000-0003-0030-1594
Claudia M RohrDepartment of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, United States of America.ORCID 0000-0003-0065-7160
John D ChanDepartment of Cell Biology, Neurobiology & Anatomy, Medical College of Wisconsin, Milwaukee, United States of America.ORCID 0000-0003-4986-972X
Medical College of Wisconsin · USQueen's University Belfast · GBUniversity of Wisconsin–Madison · US

Funding

Discovery of new molecular phenotypes for anti-schistosomal drug screeningR21AI153545 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI CHAN, JOHN D, ZAMANIAN, MOSTAFA · 2020 to 2021
$415k
Development of non-sedative, parasite-selective benzodiazepines to treat the neglected tropical disease schistosomiasisR21AI146540 · NIAID · UNIVERSITY OF WISCONSIN OSHKOSH · PI CHAN, JOHN D · 2020 to 2021
$405k
NIAID NIH HHS HHSN272201700014CNIAID NIH HHS R21 AI153545
6 · The paper itself

Abstract

Control of the neglected tropical disease schistosomiasis relies almost entirely on praziquantel (PZQ) monotherapy. How PZQ clears parasite infections remains poorly understood. Many studies have examined the effects of PZQ on worms cultured in vitro, observing outcomes such as muscle contraction. However, conditions worms are exposed to in vivo may vary considerably from in vitro experiments given the short half-life of PZQ and the importance of host immune system engagement for drug efficacy in animal models. Here, we investigated the effects of in vivo PZQ exposure on Schistosoma mansoni. Measurement of pro-apoptotic caspase activation revealed that worm death occurs only after parasites shift from the mesenteric vasculature to the liver, peaking 24 hours after drug treatment. This indicates that PZQ is not directly schistocidal, since PZQ's half-life is ~2 hours in humans and ~30 minutes in mice, and focuses attention on parasite interactions with the host immune system following the shift of worms to the liver. RNA-Seq of worms harvested from mouse livers following sub-lethal PZQ treatment revealed drug-evoked changes in the expression of putative immunomodulatory and anticoagulant gene products. Several of these gene products localized to the schistosome esophagus and may be secreted into the host circulation. These include several Kunitz-type protease inhibitors, which are also found in the secretomes of other blood feeding animals. These transcriptional changes may reflect mechanisms of parasite immune-evasion in response to chemotherapy, given the role of complement-mediated attack and the host innate/humoral immune response in parasite elimination. One of these isoforms, SmKI-1, has been shown to exhibit immunomodulatory and anti-coagulant properties. These data provide insight into the effect of in vivo PZQ exposure on S. mansoni, and the transcriptional response of parasites to the stress of chemotherapy.

Indexed as

AnimalsAnthelminticsFemaleLiverMiceNeglected DiseasesPraziquantelSchistosoma mansoniSchistosomiasis mansoniTranscription, GeneticAnthelminticsPraziquantel

Identifiers

PMID33657133
PMCPMC7959349
OpenAlexW3135479466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.